Explore the vast range of titles available.

Vaccine effectiveness (VE) studies provide real-world evidence to monitor vaccine performance and inform policy. The WHO Regional Office for the Eastern Mediterranean supported a regional study to assess the VE of COVID-19 vaccines against different clinical outcomes in four countries between June 2021 and August 2023. Health worker cohort studies were conducted in 2707 health workers in Egypt and Pakistan, of whom 171 experienced symptomatic laboratory-confirmed SARS-CoV-2 infection. Test-negative design case–control studies were conducted in Iran and Jordan in 4017 severe acute respiratory infection (SARI) patients (2347 controls and 1670 cases) during the Omicron variant dominant period. VE estimates were calculated for each study and pooled by study design for several vaccine types (BBIBP-CorV, AZD1222, BNT162b2, and mRNA-1273, among others). Among health workers, VE against symptomatic infection of a complete primary series could only be computed compared to partial vaccination, suggesting a benefit of providing an additional dose of mRNA vaccines (VE: 88.9%, 95%CI: 15.3–98.6%), while results were inconclusive for other vaccine products. Among SARI patients, VE against hospitalization of a complete primary series with any vaccine compared to non-vaccinated was 20.9% (95%CI: 4.5–34.5%). Effectiveness estimates for individual vaccines, booster doses, and secondary outcomes (intensive care unit admission and death) were inconclusive. Future VE studies will need to address challenges in both design and analysis when conducted late during a pandemic and will be able to utilize the strengthened capacities in countries.

Introduction: The family physician programme (FPP) was implemented nearly two decades ago as a major health reform. Since the health system and FPP function in a rapidly changing social and economic environment, successful expansion of the programme requires a detailed analysis of its multiple major challenges, including the crucial aspect of its funding system. This systematic review aimed to assess the challenges in the FPP relative to its financing. Methods: All published articles related to the FPP in Iran were included in this study. In particular, original qualitative studies published in English or Persian from 2011 to 2021 were included. In January 2022, international credible scholarly databases and Persian databases were searched. All selected articles were carefully studied, and the data were extracted using the sample, phenomenon of interest, design, evaluation and research type technique. The Preferred Reporting Items for Systematic Reviews and Meta-Analyses were used in preparing the study report. Results: Among 491 articles retrieved from the search strategy, 50 met the inclusion criteria after their titles and abstracts were screened. Twenty-nine studies were excluded after their full texts were reviewed. A total of 11 eligible empirical studies were finally included. Based on the results, six broad categories (budget and funding, insurance system, tariffs, payments, accountability and injustice) were identified as financial challenges. Conclusion: This study identified the challenges associated with financing among family physicians, and the results could provide guidance for policy-making in the expansion of the FPP.

Key words: vaccine effectiveness, COVID-19, immunization, evidence-informed policy-making, Eastern Mediterranean At the 73rd World Health Assembly on 19 May 2020, WHO Member States were encouraged to collaborate in advancing research and knowledge-sharing, particularly on vaccines, diagnostics and therapeutics, with funding by the private sector and governments across various domains, as a necessary measure to contain and halt the COVID-19 pandemic (1). [...]there were very few vaccine effectiveness studies in the Eastern Mediterranean Region (EMR) and there was limited or no data on specific vaccine products approved for use in EMR countries (5,6). Because EMR countries had primarily channelled their resources towards managing the pandemic's clinical impact, Member States requested WHO support in conducting vaccine effectiveness research to generate local evidence that could better inform COVID-19 vaccination policies at national level (7). [...]the leadership of the Incident Management Support Team at the WHO Regional Office for the Eastern Mediterranean (WHO/ EMRO) initiated a rapid and comprehensive evidence generation response aimed to provide technical, operational and financial support for implementing such study in the EMR (8). For the vaccine effectiveness study, WHO provided technical support to countries for the design, conceptualization and vetting of technical proposals (10,11) through regular meetings, field visits and guidance on methodologies, data collection, management, and analysis.